These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 28296257

  • 21. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.
    Juarez M, Diaz N, Johnston GI, Nayar S, Payne A, Helmer E, Cain D, Williams P, Devauchelle-Pensec V, Fisher BA, Giacomelli R, Gottenberg JE, Guggino G, Kvarnström M, Mariette X, Ng WF, Rosas J, Sánchez Bursón J, Triolo G, Barone F, Bowman SJ.
    Rheumatology (Oxford); 2021 Mar 02; 60(3):1364-1375. PubMed ID: 32949140
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome: A Randomized Clinical Trial.
    He J, Chen J, Miao M, Zhang R, Cheng G, Wang Y, Feng R, Huang B, Luan H, Jia Y, Jin Y, Zhang X, Shao M, Wang Y, Zhang X, Li J, Zhao X, Wang H, Liu T, Xiao X, Zhang X, Su Y, Mu R, Ye H, Li R, Liu X, Liu Y, Li C, Liu H, Hu F, Guo J, Liu W, Zhang WB, Jacob A, Ambrus JL, Ding C, Yu D, Sun X, Li Z.
    JAMA Netw Open; 2022 Nov 01; 5(11):e2241451. PubMed ID: 36355371
    [Abstract] [Full Text] [Related]

  • 23. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
    Bowman SJ, Fox R, Dörner T, Mariette X, Papas A, Grader-Beck T, Fisher BA, Barcelos F, De Vita S, Schulze-Koops H, Moots RJ, Junge G, Woznicki JN, Sopala MA, Luo WL, Hueber W.
    Lancet; 2022 Jan 08; 399(10320):161-171. PubMed ID: 34861168
    [Abstract] [Full Text] [Related]

  • 24. Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
    Dörner T, Posch MG, Li Y, Petricoul O, Cabanski M, Milojevic JM, Kamphausen E, Valentin MA, Simonett C, Mooney L, Hüser A, Gram H, Wagner FD, Oliver SJ.
    Ann Rheum Dis; 2019 May 08; 78(5):641-647. PubMed ID: 30826774
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of the clinical efficacy of Biotène Oral Balance in patients with secondary Sjögren's syndrome: a pilot study.
    Aliko A, Alushi A, Tafaj A, Isufi R.
    Rheumatol Int; 2012 Sep 08; 32(9):2877-81. PubMed ID: 21898068
    [Abstract] [Full Text] [Related]

  • 26. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome.
    Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, Ramos-Casals M, Dörner T, Bombardieri S, Hachulla E, Brun JG, Kruize AA, Praprotnik S, Tomsic M, Gottenberg JE, Devauchelle V, Devita S, Vollenweider C, Mandl T, Tzioufas A, Carsons S, Saraux A, Sutcliffe N, Vitali C, Bowman SJ, EULAR Sjögren's Task Force.
    Ann Rheum Dis; 2011 Jun 08; 70(6):968-72. PubMed ID: 21345815
    [Abstract] [Full Text] [Related]

  • 27. Interleukin-1 inhibition and fatigue in primary Sjögren's syndrome--a double blind, randomised clinical trial.
    Norheim KB, Harboe E, Gøransson LG, Omdal R.
    PLoS One; 2012 Jun 08; 7(1):e30123. PubMed ID: 22253903
    [Abstract] [Full Text] [Related]

  • 28. [Treatment of oral dryness in Sjögren's syndrome].
    Mariette X.
    Rev Med Interne; 2004 Apr 08; 25(4):287-93. PubMed ID: 15112663
    [Abstract] [Full Text] [Related]

  • 29. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20).
    Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S, Roudaut A, Jamin C, Renaudineau Y, Roué IQ, Cochener B, Youinou P, Saraux A.
    Arthritis Rheum; 2007 Mar 15; 57(2):310-7. PubMed ID: 17330280
    [Abstract] [Full Text] [Related]

  • 30. Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis.
    St Clair EW, Levesque MC, Prak ET, Vivino FB, Alappatt CJ, Spychala ME, Wedgwood J, McNamara J, Moser Sivils KL, Fisher L, Cohen P, Autoimmunity Centers of Excellence.
    Arthritis Rheum; 2013 Apr 15; 65(4):1097-106. PubMed ID: 23334994
    [Abstract] [Full Text] [Related]

  • 31. Rituximab therapy in primary Sjögren's syndrome with interstitial lung disease: a retrospective cohort study.
    Chen MH, Chen CK, Chou HP, Chen MH, Tsai CY, Chang DM.
    Clin Exp Rheumatol; 2016 Apr 15; 34(6):1077-1084. PubMed ID: 27607895
    [Abstract] [Full Text] [Related]

  • 32. Treatment Guidelines for Rheumatologic Manifestations of Sjögren's Syndrome: Use of Biologic Agents, Management of Fatigue, and Inflammatory Musculoskeletal Pain.
    Carsons SE, Vivino FB, Parke A, Carteron N, Sankar V, Brasington R, Brennan MT, Ehlers W, Fox R, Scofield H, Hammitt KM, Birnbaum J, Kassan S, Mandel S.
    Arthritis Care Res (Hoboken); 2017 Apr 15; 69(4):517-527. PubMed ID: 27390247
    [Abstract] [Full Text] [Related]

  • 33. Treatment of primary Sjögren syndrome with rituximab: a randomized trial.
    Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, Le Guern V, Sibilia J, Gottenberg JE, Chiche L, Hachulla E, Hatron PY, Goeb V, Hayem G, Morel J, Zarnitsky C, Dubost JJ, Pers JO, Nowak E, Saraux A.
    Ann Intern Med; 2014 Feb 18; 160(4):233-42. PubMed ID: 24727841
    [Abstract] [Full Text] [Related]

  • 34. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca.
    Petrone D, Condemi JJ, Fife R, Gluck O, Cohen S, Dalgin P.
    Arthritis Rheum; 2002 Mar 18; 46(3):748-54. PubMed ID: 11920411
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.
    Carubbi F, Cipriani P, Marrelli A, Benedetto P, Ruscitti P, Berardicurti O, Pantano I, Liakouli V, Alvaro S, Alunno A, Manzo A, Ciccia F, Gerli R, Triolo G, Giacomelli R.
    Arthritis Res Ther; 2013 Oct 30; 15(5):R172. PubMed ID: 24286296
    [Abstract] [Full Text] [Related]

  • 36. Long-term effectiveness of a novel intra-oral electro-stimulator for the treatment of dry mouth in patients with Sjogren's syndrome: A randomised sham-controlled feasibility study (LEONIDAS-1).
    Fedele S, Al-Hamad A, Mercadante V, Porter S, Isenberg D, Poveda-Gallego A, Brown ST.
    J Oral Pathol Med; 2023 Aug 30; 52(7):619-627. PubMed ID: 37220073
    [Abstract] [Full Text] [Related]

  • 37. Pain, xerostomia, and younger age are major determinants of fatigue in Korean patients with primary Sjögren's syndrome: a cohort study.
    Koh JH, Kwok SK, Lee J, Son CN, Kim JM, Kim HO, Park SH, Sung YK, Choe JY, Lee SS, Park SH.
    Scand J Rheumatol; 2017 Jan 30; 46(1):49-55. PubMed ID: 27098775
    [Abstract] [Full Text] [Related]

  • 38. Combined interventional sialendoscopy and intraductal steroid therapy for recurrent sialadenitis in Sjögren's syndrome: Results of a pilot monocentric trial.
    Capaccio P, Canzi P, Torretta S, Rossi V, Benazzo M, Bossi A, Vitali C, Cavagna L, Pignataro L.
    Clin Otolaryngol; 2018 Feb 30; 43(1):96-102. PubMed ID: 28585263
    [Abstract] [Full Text] [Related]

  • 39. Effects of rituximab therapy on quality of life in patients with primary Sjögren's syndrome.
    Devauchelle-Pensec V, Morvan J, Rat AC, Jousse-Joulin S, Pennec Y, Pers JO, Jamin C, Renaudineau Y, Quintin-Roué I, Cochener B, Youinou P, Saraux A.
    Clin Exp Rheumatol; 2011 Feb 30; 29(1):6-12. PubMed ID: 21345287
    [Abstract] [Full Text] [Related]

  • 40. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.
    Baer AN, Gottenberg JE, St Clair EW, Sumida T, Takeuchi T, Seror R, Foulks G, Nys M, Mukherjee S, Wong R, Ray N, Bootsma H.
    Ann Rheum Dis; 2021 Mar 30; 80(3):339-348. PubMed ID: 33168545
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.